RE: Rns , assays , incredible. 23 m at 1.51%7 Sep 2022 13:10
Alert,
Would it not be commercial suicide for PREM to given the remaining 50% offtake to the Chinese? Then they would have 100% of the offtake, effectively giving them control of Zulu's offtake and significantly reducing competition for a potential sale of Zulu in the future?
My strong preference would be for PREM not to sell any further offtake rights until they are selling Zulu, should they go down that road. It is also worth noting what Suzhou paid for the 50% offtake along with other rights. Suzhou previously paid 0.4p per share for 3b shares. Shares were trading at ~0.32p at the time. There are two ways to look at this, recognising Suzhou got a lot more than just 3b shares through the deal.
(1). Suzhou paid 25% above the odds (0.4p v 0.32p available in the market, resulting in a premium of £2.4m) for the 3b shares but they got all of the rights listed below for free.
i. Exclusive offtake rights on commercial terms to the marketing and sale of 50 per cent of all spodumene produced at Zulu ("Offtake Rights");
ii. An irrevocable right of first refusal for 180 days from the date of the Subscription to match any further equity or loan related funding that is contemplated by Premier, in particular any deal relating to Zulu, on terms no worse than those offered by another potential investor;
iii. A right of participation in any future funding so as to maintain Suzhou TA&A's shareholding of 13.38 per cent in Premier at all times; and
iv. A right to appoint one director to serve on the boards of Premier, Zulu Lithium Mauritius Limited, and Zulu Lithium (Private) Limited ("Board Appointment")
or (2), Suzhou paid market value for the 3b shares and managed to get all of the other rights listed above for £2.4m.
Bickmaster